229 related articles for article (PubMed ID: 22705889)
1. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin.
Zhang P; Gruber A; Kasuda S; Kimmelstiel C; O'Callaghan K; Cox DH; Bohm A; Baleja JD; Covic L; Kuliopulos A
Circulation; 2012 Jul; 126(1):83-91. PubMed ID: 22705889
[TBL] [Abstract][Full Text] [Related]
2. PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study.
Kuliopulos A; Gurbel PA; Rade JJ; Kimmelstiel CD; Turner SE; Bliden KP; Fletcher EK; Cox DH; Covic L;
Arterioscler Thromb Vasc Biol; 2020 Dec; 40(12):2990-3003. PubMed ID: 33028101
[TBL] [Abstract][Full Text] [Related]
3. Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.
Gurbel PA; Bliden KP; Turner SE; Tantry US; Gesheff MG; Barr TP; Covic L; Kuliopulos A
Arterioscler Thromb Vasc Biol; 2016 Jan; 36(1):189-97. PubMed ID: 26681756
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.
Wielders SJ; Bennaghmouch A; Reutelingsperger CP; Bevers EM; Lindhout T
J Thromb Haemost; 2007 Mar; 5(3):571-6. PubMed ID: 17166251
[TBL] [Abstract][Full Text] [Related]
5. Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.
Rana R; Huang T; Koukos G; Fletcher EK; Turner SE; Shearer A; Gurbel PA; Rade JJ; Kimmelstiel CD; Bliden KP; Covic L; Kuliopulos A
Arterioscler Thromb Vasc Biol; 2018 Jun; 38(6):1368-1380. PubMed ID: 29622563
[TBL] [Abstract][Full Text] [Related]
6. Preventing platelet thrombosis with a PAR1 pepducin.
Abdel-Latif A; Smyth SS
Circulation; 2012 Jul; 126(1):13-5. PubMed ID: 22705888
[No Abstract] [Full Text] [Related]
7. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
[TBL] [Abstract][Full Text] [Related]
8. Differential anti-thrombotic benefit and bleeding risk profiles of antagonists of protease-activated receptor 1 and 4 in Cynomolgus Macaques.
Wickham LA; Sitko G; Stranieri-Michener M; Handt L; Basso A; Fried S; Chu L; Maderia M; Owens K; Castriota G; Chen Z; Metzger JM; Imbriglio J; Wang X; Cai TQ
Thromb Res; 2016 Sep; 145():133-9. PubMed ID: 27318768
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist.
Dumas M; Nadal-Wollbold F; Gaussem P; Perez M; Mirault T; Létienne R; Bourbon T; Grelac F; Le Grand B; Bachelot-Loza C
Br J Pharmacol; 2012 Mar; 165(6):1827-1835. PubMed ID: 21913899
[TBL] [Abstract][Full Text] [Related]
10. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
[TBL] [Abstract][Full Text] [Related]
11. Platelet biology and implications for antiplatelet therapy in atherothrombotic disease.
Montalescot G
Clin Appl Thromb Hemost; 2011 Aug; 17(4):371-80. PubMed ID: 20566574
[TBL] [Abstract][Full Text] [Related]
12. The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions.
Lee H; Sturgeon SA; Jackson SP; Hamilton JR
Thromb Haemost; 2012 Feb; 107(2):328-37. PubMed ID: 22187047
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice.
Lee H; Sturgeon SA; Mountford JK; Jackson SP; Hamilton JR
Br J Pharmacol; 2012 Aug; 166(7):2188-97. PubMed ID: 22428607
[TBL] [Abstract][Full Text] [Related]
14. Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach.
Covic L; Kuliopulos A
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30065181
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
[TBL] [Abstract][Full Text] [Related]
16. Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention.
Kimmelstiel C; Zhang P; Kapur NK; Weintraub A; Krishnamurthy B; Castaneda V; Covic L; Kuliopulos A
Circ Cardiovasc Interv; 2011 Apr; 4(2):171-9. PubMed ID: 21364148
[TBL] [Abstract][Full Text] [Related]
17. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.
Wong PC; Seiffert D; Bird JE; Watson CA; Bostwick JS; Giancarli M; Allegretto N; Hua J; Harden D; Guay J; Callejo M; Miller MM; Lawrence RM; Banville J; Guy J; Maxwell BD; Priestley ES; Marinier A; Wexler RR; Bouvier M; Gordon DA; Schumacher WA; Yang J
Sci Transl Med; 2017 Jan; 9(371):. PubMed ID: 28053157
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
Jennings LK
Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
[TBL] [Abstract][Full Text] [Related]
19. Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases.
Ahn HS; Chackalamannil S; Boykow G; Graziano MP; Foster C
Curr Pharm Des; 2003; 9(28):2349-65. PubMed ID: 14529396
[TBL] [Abstract][Full Text] [Related]
20. New targets for antithrombotic drugs.
Thiagarajan P
Am J Cardiovasc Drugs; 2002; 2(4):227-35. PubMed ID: 14727968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
